InvestSMART

Neurotech International Limited (ASX: NTI) - Announcements

Current share price for NTI : $0.019 0.001 (5.56%)+

ASX company news and announcements for Neurotech International Limited (NTI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurotech International Limited (NTI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurotech International Limited (NTI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurotech International Limited (NTI)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 Appointment of Joint Company Secretary 21 Mar 2024 4:10PM $0.110 $0.019 fallen by 82.73%
$31 Neurotech Presentation at NWR Virtual Healthcare Conference 21 Mar 2024 8:49AM $0.100 $0.019 fallen by 81%
$31 Neurotech to present at NWR Virtual Healthcare Conference 19 Mar 2024 11:49AM $0.096 $0.019 fallen by 80.21%
$31 Secondary Trading Notice 15 Mar 2024 7:41PM $0.098 $0.019 fallen by 80.61%
$31 Notification regarding unquoted securities - NTI 15 Mar 2024 6:41PM $0.098 $0.019 fallen by 80.61%
$31 Application for quotation of securities - NTI 15 Mar 2024 6:41PM $0.098 $0.019 fallen by 80.61%
$31 NTI to Present at Spark Plus Conference in Singapore 13 Mar 2024 4:18PM $0.099 $0.019 fallen by 80.81%
$31 Rett Syndrome Patients to Receive NTI164 for 52 Weeks 13 Mar 2024 8:18AM $0.091 $0.019 fallen by 79.12%
$31 Notification of cessation of securities - NTI 12 Mar 2024 6:14PM $0.091 $0.019 fallen by 79.12%
$31 Secondary Trading Notice 11 Mar 2024 1:51PM $0.100 $0.019 fallen by 81%
$31 Notification regarding unquoted securities - NTI 8 Mar 2024 4:10PM $0.098 $0.019 fallen by 80.61%
$31 Application for quotation of securities - NTI 8 Mar 2024 4:08PM $0.099 $0.019 fallen by 80.81%
$31 Initial ESG Report 27 Feb 2024 7:59AM $0.115 $0.019 fallen by 83.48%
$31 Appendix 4D and Half Year Accounts 27 Feb 2024 7:59AM $0.115 $0.019 fallen by 83.48%
$31 Investor Presentation 21 Feb 2024 8:02AM $0.105 $0.019 fallen by 81.90%
$31 PANDAS/PANS Patients Show Continued Clinical Improvement 21 Feb 2024 8:02AM $0.105 $0.019 fallen by 81.90%
$31 Secondary Trading Notice 14 Feb 2024 5:11PM $0.092 $0.019 fallen by 79.35%
$31 Notification regarding unquoted securities - NTI 14 Feb 2024 4:55PM $0.092 $0.019 fallen by 79.35%
$31 Application for quotation of securities - NTI 14 Feb 2024 4:53PM $0.092 $0.019 fallen by 79.35%
$31 Neurotech Receives Additional HREC Approval in Autism 13 Feb 2024 8:02AM $0.097 $0.019 fallen by 80.41%
$31 ASD Phase I/II Patients Exceed Treatment Beyond 90 Weeks 7 Feb 2024 9:29AM $0.100 $0.019 fallen by 81%
$31 Amended Change of Director's Interest Notice 30 Jan 2024 10:59AM $0.091 $0.019 fallen by 79.12%
$31 Change of Director's Interest Notice 30 Jan 2024 8:13AM $0.090 $0.019 fallen by 78.89%
$31 NTI Receives HREC Approval for Cerebral Palsy Trial 29 Jan 2024 8:15AM $0.085 $0.019 fallen by 77.65%
$31 Quarterly Activities/Appendix 4C Cash Flow Report 24 Jan 2024 8:20AM $0.077 $0.019 fallen by 75.32%

176 - 200 of 700 results

Page 8 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.